Table 1 The clinical and pathological characteristics of ungrouped, and grouped patients before or after PSM
Variables | Total patients (n = 544) | Before PSM | After PSMa | ||||
|---|---|---|---|---|---|---|---|
α-HBDH-low group (n = 394) | α-HBDH-high group (n = 150) | P value | α-HBDH-low group (n = 300) | α-HBDH-high group (n = 150) | P value | ||
Age (IQR) | 68.00 (61.00–75.00) | 68.00 (61.00–75.00) | 69.00 (64.00–75.00) | 0.623 | 68.00 (61.00–75.00) | 69.00 (64.00–75.00) | 0.623 |
Age, n (%) | 0.052 | 0.079 | |||||
< 65 | 191 (35.11%) | 148 (37.56%) | 43 (28.67%) | 111 (37.00%) | 43 (28.67%) | ||
≥ 65 | 353 (64.89%) | 246 (62.44%) | 107 (71.33%) | 189 (63.00%) | 107 (71.33%) | ||
Body mass index (IQR) | 22.67 (20.76–25.35) | 22.66 (20.77–25.43) | 22.76 (19.90–24.35) | 0.490 | 22.66 (20.77–25.43) | 22.70 (19.90–24.35) | 0.710 |
α-HBDH (IQR) | 139.50 (122.75–161.00) | 131.00 (119.00–142.00) | 175.50 (164.25–203.50) | < 0.001 | 133.00 (119.80–143.00) | 175.50 (164.20–203.50) | < 0.001 |
LDH (IQR) | 179.00 (157.75–202.00) | 168.00 (151.00–182.00) | 222.50 (205.00–251.75) | < 0.001 | 169.00 (150.80–182.20) | 222.50 (205.00–251.80) | |
LDH, n (%) | < 0.001 | < 0.001 | |||||
≤ 200 | 401 (73.71%) | 372 (94.42%) | 29 (19.33%) | 286 (95.33%) | 29 (19.33%) | ||
> 200 | 143 (26.29) | 22 (5.58%) | 121 (80.67%) | 14 (4.67%) | 121 (80.67%) | ||
Albumin (IQR) | 40.55 (37.00–43.10) | 40.80 (37.80–43.30) | 39.60 (35.00–43.00) | 0.025 | 40.20 (38.20–43.20) | 39.60 (35.00–43.00) | 0.058 |
Gender, n (%) | < 0.001 | 0.124 | |||||
Female | 241 (44.30%) | 153 (38.83%) | 88 (58.67%) | 153 (51.00%) | 88 (58.67%) | ||
Male | 303 (55.70%) | 241 (61.17%) | 62 (41.33%) | 147 (49.00%) | 62 (41.43%) | ||
Tumor location, n (%) | 0.007 | 0.514 | |||||
Renal pelvis | 271 (49.91%) | 190 (48.35%) | 81 (54.00%) | 170 (56.67%) | 81 (54.00%) | ||
Ureter | 209 (38.49%) | 165 (41.98%) | 44 (29.33%) | 92 (30.67%) | 44 (29.33%) | ||
Both | 63 (11.60%) | 38 (9.67%) | 25 (16.67%) | 38 (12.67%) | 25 (16.67%) | ||
Tumor size, n (%) | 0.392 | 0.325 | |||||
< 3 | 186 (34.38%) | 139 (35.46%) | 47 (31.54%) | 108 (36.24%) | 47 (31.54%) | ||
≥ 3 | 355 (65.62%) | 253 (64.54%) | 102 (68.46%) | 190 (63.76%) | 102 (68.46%) | ||
Tumor stage, n (%) | 0.128 | 0.461 | |||||
≤ pT2 | 272 (50.28%) | 205 (52.30%) | 67 (44.97%) | 145 (48.66%) | 67 (44.97%) | ||
> pT2 | 269 (49.72%) | 187 (47.70%) | 82 (55.03%) | 153 (51.34%) | 82 (55.03%) | ||
Tumor grade, n (%) | 0.052 | 0.354 | |||||
Low | 129 (23.89%) | 102 (26.09%) | 27 (18.12%) | 65 (21.89%) | 27 (18.12%) | ||
High | 411 (76.11%) | 289 (73.91%) | 122 (81.88%) | 232 (78.11%) | 122 (81.88%) | ||
Lymph node status, n (%) | 0.005 | 0.084 | |||||
pN0/x | 487 (89.85%) | 362 (92.11%) | 125 (83.89%) | 269 (89.67%) | 126 (84.00%) | ||
pN + | 55 (10.15%) | 31 (7.89%) | 24 (16.11%) | 31 (10.33%) | 24 (16.00%) | ||
Lymphovascular invasion, n (%) | 0.065 | 0.156 | |||||
Yes | 87 (16.08%) | 56 (14.29%) | 31 (20.81%) | 46 (15.44%) | 31 (20.81%) | ||
No | 454 (83.92%) | 336 (85.71%) | 118 (79.19%) | 252 (84.56%) | 118 (79.19%) | ||
Tumor architecture, n (%) | 0.290 | 0.584 | |||||
Sessile | 246 (45.81%) | 185 (47.19%) | 61 (42.07%) | 134 (44.82%) | 61 (42.07%) | ||
Papillary | 291 (54.19%) | 207 (52.81%) | 84 (57.93%) | 165 (55.18%) | 84 (57.93%) | ||
Surgery margin, n (%) | 0.139 | 0.077 | |||||
Positive | 43 (7.95%) | 27 (6.89%) | 16 (10.74%) | 18 (6.04%) | 16 (10.74%) | ||
Negative | 498 (92.05%) | 365 (93.11%) | 133 (89.26%) | 280 (94.96%) | 133 (89.26%) | ||
Tumor necrosis, n (%) | 0.891 | 0.487 | |||||
Yes | 92 (16.91%) | 67 (17.01%) | 25 (16.67%) | 42 (14.00%) | 25 (16.67%) | ||
No | 452 (83.09%) | 327 (82.99%) | 125 (83.33%) | 258 (86.00%) | 125 (83.33%) | ||
Adjuvant systemic chemotherapy, n (%) | 0.265 | 0.708 | |||||
Yes | 84 (14.14%) | 55 (14.00%) | 29 (19.32%) | 45 (15.00%) | 29 (19.32%) | ||
No | 460 (85.86%) | 339 (86.00%) | 121 (80.68%) | 255 (85.00%) | 121 (80.68%) | ||